⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PDSB News
PDS Biotechnology Corporation Common Stock
Form 8-K
sec.gov
PDSB
Form 8-K
sec.gov
PDSB
Form 8-K
sec.gov
PDSB
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
globenewswire.com
PDSB
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
globenewswire.com
PDSB
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
globenewswire.com
PDSB
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
globenewswire.com
PDSB
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
prnewswire.com
ONCY
CGON
ZNTL
AVBP
PDSB
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
globenewswire.com
PDSB